Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
[PubMed - indexed for MEDLINE]
2.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

PMID:
21050119
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
[PubMed - indexed for MEDLINE]
Free Article
4.

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Röshammar D, Simonsson US, Ekvall H, Flamholc L, Ormaasen V, Vesterbacka J, Wallmark E, Ashton M, Gisslén M.

J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):727-42. doi: 10.1007/s10928-011-9217-1. Epub 2011 Oct 2.

PMID:
21964996
[PubMed - indexed for MEDLINE]
5.

Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Calcagno A, D'Avolio A, Di Perri G, Bonora S.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):e118-9. doi: 10.1097/QAI.0b013e3182809d9f. No abstract available.

PMID:
24135736
[PubMed - indexed for MEDLINE]
6.

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Cusini A, Ledergerber B, Widmer N, Günthard HF.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):e14-5. doi: 10.1097/QAI.0b013e3182a82281. No abstract available.

PMID:
24047974
[PubMed - indexed for MEDLINE]
7.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
[PubMed - indexed for MEDLINE]
8.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A.

J Infect. 2012 Sep;65(3):239-45. doi: 10.1016/j.jinf.2012.04.007. Epub 2012 Apr 17.

PMID:
22522289
[PubMed - indexed for MEDLINE]
9.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168
[PubMed - indexed for MEDLINE]
10.

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

Taylor S, Jayasuriya A, Fisher M, Allan S, Wilkins E, Gilleran G, Heald L, Fidler S, Owen A, Back D, Smit E.

J Antimicrob Chemother. 2012 Mar;67(3):675-80. doi: 10.1093/jac/dkr491. Epub 2011 Dec 14.

PMID:
22169189
[PubMed - indexed for MEDLINE]
Free Article
11.

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.

Andersson LM, Vesterbacka J, Blaxhult A, Flamholc L, Nilsson S, Ormaasen V, Sönnerborg A, Gisslén M.

Scand J Infect Dis. 2013 Jul;45(7):543-51. doi: 10.3109/00365548.2012.756985. Epub 2013 Jan 7.

PMID:
23294034
[PubMed - indexed for MEDLINE]
12.

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B.

HIV Clin Trials. 2002 Jan-Feb;3(1):27-35.

PMID:
11819183
[PubMed - indexed for MEDLINE]
13.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team.

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
[PubMed - indexed for MEDLINE]
14.

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, Cameron DW.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):371-5.

PMID:
10458617
[PubMed - indexed for MEDLINE]
15.

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S.

J Antimicrob Chemother. 2005 Aug;56(2):380-7. Epub 2005 Jul 4.

PMID:
15996972
[PubMed - indexed for MEDLINE]
Free Article
16.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group.

J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21.

PMID:
22915463
[PubMed - indexed for MEDLINE]
Free Article
17.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group.

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

PMID:
18195140
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
19.

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group.

Clin Infect Dis. 2010 Oct 1;51(7):855-64. doi: 10.1086/656363.

PMID:
20735258
[PubMed - indexed for MEDLINE]
Free Article
20.

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B.

Antimicrob Agents Chemother. 2003 Jan;47(1):238-43.

PMID:
12499197
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk